nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosamprenavir—CYP3A4—Tamoxifen—pancreatic cancer	0.119	0.24	CbGbCtD
Fosamprenavir—CYP3A4—Erlotinib—pancreatic cancer	0.101	0.204	CbGbCtD
Fosamprenavir—CYP3A4—Irinotecan—pancreatic cancer	0.0915	0.185	CbGbCtD
Fosamprenavir—CYP3A4—Docetaxel—pancreatic cancer	0.067	0.135	CbGbCtD
Fosamprenavir—CYP3A4—Sunitinib—pancreatic cancer	0.0667	0.135	CbGbCtD
Fosamprenavir—CYP3A4—Doxorubicin—pancreatic cancer	0.05	0.101	CbGbCtD
Fosamprenavir—Malnutrition—Sunitinib—pancreatic cancer	0.00193	0.00382	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Fluorouracil—pancreatic cancer	0.00192	0.0038	CcSEcCtD
Fosamprenavir—Myalgia—Tamoxifen—pancreatic cancer	0.00191	0.0038	CcSEcCtD
Fosamprenavir—Myocardial infarction—Fluorouracil—pancreatic cancer	0.00191	0.00378	CcSEcCtD
Fosamprenavir—Flatulence—Sunitinib—pancreatic cancer	0.0019	0.00376	CcSEcCtD
Fosamprenavir—Myalgia—Erlotinib—pancreatic cancer	0.00189	0.00376	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—pancreatic cancer	0.00188	0.00373	CcSEcCtD
Fosamprenavir—Haemoglobin—Irinotecan—pancreatic cancer	0.00183	0.00363	CcSEcCtD
Fosamprenavir—Haemorrhage—Irinotecan—pancreatic cancer	0.00182	0.00361	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Irinotecan—pancreatic cancer	0.00179	0.00355	CcSEcCtD
Fosamprenavir—Haemoglobin—Gemcitabine—pancreatic cancer	0.00178	0.00354	CcSEcCtD
Fosamprenavir—Nervous system disorder—Erlotinib—pancreatic cancer	0.00178	0.00353	CcSEcCtD
Fosamprenavir—Haemorrhage—Gemcitabine—pancreatic cancer	0.00178	0.00352	CcSEcCtD
Fosamprenavir—Skin disorder—Erlotinib—pancreatic cancer	0.00176	0.0035	CcSEcCtD
Fosamprenavir—Angioedema—Sunitinib—pancreatic cancer	0.00176	0.00349	CcSEcCtD
Fosamprenavir—Haemoglobin—Fluorouracil—pancreatic cancer	0.00175	0.00348	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Gemcitabine—pancreatic cancer	0.00175	0.00348	CcSEcCtD
Fosamprenavir—Anorexia—Tamoxifen—pancreatic cancer	0.00175	0.00347	CcSEcCtD
Fosamprenavir—Haemorrhage—Fluorouracil—pancreatic cancer	0.00175	0.00346	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Gemcitabine—pancreatic cancer	0.00174	0.00346	CcSEcCtD
Fosamprenavir—Inflammation—Epirubicin—pancreatic cancer	0.00174	0.00346	CcSEcCtD
Fosamprenavir—Urethral disorder—Gemcitabine—pancreatic cancer	0.00174	0.00345	CcSEcCtD
Fosamprenavir—Anorexia—Erlotinib—pancreatic cancer	0.00173	0.00343	CcSEcCtD
Fosamprenavir—Cardiac disorder—Irinotecan—pancreatic cancer	0.00169	0.00335	CcSEcCtD
Fosamprenavir—Erythema multiforme—Gemcitabine—pancreatic cancer	0.00168	0.00333	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Tamoxifen—pancreatic cancer	0.00167	0.00332	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Erlotinib—pancreatic cancer	0.00165	0.00328	CcSEcCtD
Fosamprenavir—Cardiac disorder—Gemcitabine—pancreatic cancer	0.00165	0.00327	CcSEcCtD
Fosamprenavir—Immune system disorder—Irinotecan—pancreatic cancer	0.00165	0.00326	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Docetaxel—pancreatic cancer	0.00164	0.00325	CcSEcCtD
Fosamprenavir—Myalgia—Sunitinib—pancreatic cancer	0.00164	0.00325	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—pancreatic cancer	0.00163	0.00323	CcSEcCtD
Fosamprenavir—Inflammation—Doxorubicin—pancreatic cancer	0.00161	0.0032	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Docetaxel—pancreatic cancer	0.00161	0.00318	CcSEcCtD
Fosamprenavir—Immune system disorder—Gemcitabine—pancreatic cancer	0.0016	0.00318	CcSEcCtD
Fosamprenavir—Decreased appetite—Tamoxifen—pancreatic cancer	0.0016	0.00316	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00158	0.00314	CcSEcCtD
Fosamprenavir—Fatigue—Tamoxifen—pancreatic cancer	0.00158	0.00314	CcSEcCtD
Fosamprenavir—Decreased appetite—Erlotinib—pancreatic cancer	0.00158	0.00313	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00157	0.00311	CcSEcCtD
Fosamprenavir—Fatigue—Erlotinib—pancreatic cancer	0.00157	0.0031	CcSEcCtD
Fosamprenavir—Flatulence—Irinotecan—pancreatic cancer	0.00156	0.0031	CcSEcCtD
Fosamprenavir—Nervous system disorder—Sunitinib—pancreatic cancer	0.00154	0.00306	CcSEcCtD
Fosamprenavir—Skin disorder—Sunitinib—pancreatic cancer	0.00153	0.00303	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.0015	0.00298	CcSEcCtD
Fosamprenavir—Anorexia—Sunitinib—pancreatic cancer	0.0015	0.00297	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00148	0.00294	CcSEcCtD
Fosamprenavir—Neutropenia—Docetaxel—pancreatic cancer	0.00147	0.00292	CcSEcCtD
Fosamprenavir—Abdominal pain—Tamoxifen—pancreatic cancer	0.00145	0.00288	CcSEcCtD
Fosamprenavir—Abdominal pain—Erlotinib—pancreatic cancer	0.00144	0.00285	CcSEcCtD
Fosamprenavir—Body temperature increased—Erlotinib—pancreatic cancer	0.00144	0.00285	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.00143	0.00284	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Epirubicin—pancreatic cancer	0.00141	0.0028	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00139	0.00276	CcSEcCtD
Fosamprenavir—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.00138	0.00274	CcSEcCtD
Fosamprenavir—Myocardial infarction—Docetaxel—pancreatic cancer	0.00138	0.00273	CcSEcCtD
Fosamprenavir—Decreased appetite—Sunitinib—pancreatic cancer	0.00137	0.00271	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00136	0.00269	CcSEcCtD
Fosamprenavir—Fatigue—Sunitinib—pancreatic cancer	0.00136	0.00269	CcSEcCtD
Fosamprenavir—Hypersensitivity—Tamoxifen—pancreatic cancer	0.00135	0.00268	CcSEcCtD
Fosamprenavir—Asthenia—Tamoxifen—pancreatic cancer	0.00132	0.00261	CcSEcCtD
Fosamprenavir—Myalgia—Gemcitabine—pancreatic cancer	0.00132	0.00261	CcSEcCtD
Fosamprenavir—Diabetes mellitus—Doxorubicin—pancreatic cancer	0.00131	0.00259	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—pancreatic cancer	0.00131	0.00259	CcSEcCtD
Fosamprenavir—Asthenia—Erlotinib—pancreatic cancer	0.0013	0.00258	CcSEcCtD
Fosamprenavir—Pruritus—Tamoxifen—pancreatic cancer	0.0013	0.00257	CcSEcCtD
Fosamprenavir—Myalgia—Fluorouracil—pancreatic cancer	0.00129	0.00256	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00129	0.00255	CcSEcCtD
Fosamprenavir—Pruritus—Erlotinib—pancreatic cancer	0.00128	0.00255	CcSEcCtD
Fosamprenavir—Nervous system disorder—Irinotecan—pancreatic cancer	0.00127	0.00252	CcSEcCtD
Fosamprenavir—Haemoglobin—Docetaxel—pancreatic cancer	0.00127	0.00251	CcSEcCtD
Fosamprenavir—Haemorrhage—Docetaxel—pancreatic cancer	0.00126	0.0025	CcSEcCtD
Fosamprenavir—Diarrhoea—Tamoxifen—pancreatic cancer	0.00126	0.00249	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Docetaxel—pancreatic cancer	0.00124	0.00247	CcSEcCtD
Fosamprenavir—Abdominal pain—Sunitinib—pancreatic cancer	0.00124	0.00246	CcSEcCtD
Fosamprenavir—Body temperature increased—Sunitinib—pancreatic cancer	0.00124	0.00246	CcSEcCtD
Fosamprenavir—Diarrhoea—Erlotinib—pancreatic cancer	0.00124	0.00246	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Docetaxel—pancreatic cancer	0.00124	0.00245	CcSEcCtD
Fosamprenavir—Nervous system disorder—Gemcitabine—pancreatic cancer	0.00124	0.00245	CcSEcCtD
Fosamprenavir—Urethral disorder—Docetaxel—pancreatic cancer	0.00124	0.00245	CcSEcCtD
Fosamprenavir—Anorexia—Irinotecan—pancreatic cancer	0.00123	0.00245	CcSEcCtD
Fosamprenavir—Skin disorder—Gemcitabine—pancreatic cancer	0.00123	0.00243	CcSEcCtD
Fosamprenavir—Nervous system disorder—Fluorouracil—pancreatic cancer	0.00122	0.00241	CcSEcCtD
Fosamprenavir—Dizziness—Tamoxifen—pancreatic cancer	0.00121	0.00241	CcSEcCtD
Fosamprenavir—Anorexia—Gemcitabine—pancreatic cancer	0.0012	0.00238	CcSEcCtD
Fosamprenavir—Dizziness—Erlotinib—pancreatic cancer	0.0012	0.00238	CcSEcCtD
Fosamprenavir—Erythema multiforme—Docetaxel—pancreatic cancer	0.00119	0.00236	CcSEcCtD
Fosamprenavir—Anorexia—Fluorouracil—pancreatic cancer	0.00118	0.00234	CcSEcCtD
Fosamprenavir—Cardiac disorder—Docetaxel—pancreatic cancer	0.00117	0.00232	CcSEcCtD
Fosamprenavir—Vomiting—Tamoxifen—pancreatic cancer	0.00117	0.00231	CcSEcCtD
Fosamprenavir—Hypersensitivity—Sunitinib—pancreatic cancer	0.00116	0.0023	CcSEcCtD
Fosamprenavir—Rash—Tamoxifen—pancreatic cancer	0.00116	0.00229	CcSEcCtD
Fosamprenavir—Dermatitis—Tamoxifen—pancreatic cancer	0.00116	0.00229	CcSEcCtD
Fosamprenavir—Vomiting—Erlotinib—pancreatic cancer	0.00115	0.00229	CcSEcCtD
Fosamprenavir—Headache—Tamoxifen—pancreatic cancer	0.00115	0.00228	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.00115	0.00228	CcSEcCtD
Fosamprenavir—Rash—Erlotinib—pancreatic cancer	0.00115	0.00227	CcSEcCtD
Fosamprenavir—Dermatitis—Erlotinib—pancreatic cancer	0.00114	0.00227	CcSEcCtD
Fosamprenavir—Immune system disorder—Docetaxel—pancreatic cancer	0.00114	0.00226	CcSEcCtD
Fosamprenavir—Headache—Erlotinib—pancreatic cancer	0.00114	0.00226	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00113	0.00224	CcSEcCtD
Fosamprenavir—Asthenia—Sunitinib—pancreatic cancer	0.00113	0.00224	CcSEcCtD
Fosamprenavir—Decreased appetite—Irinotecan—pancreatic cancer	0.00113	0.00223	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.00112	0.00222	CcSEcCtD
Fosamprenavir—Fatigue—Irinotecan—pancreatic cancer	0.00112	0.00221	CcSEcCtD
Fosamprenavir—Pruritus—Sunitinib—pancreatic cancer	0.00111	0.00221	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.00111	0.00219	CcSEcCtD
Fosamprenavir—Malnutrition—Docetaxel—pancreatic cancer	0.0011	0.00217	CcSEcCtD
Fosamprenavir—Decreased appetite—Gemcitabine—pancreatic cancer	0.0011	0.00217	CcSEcCtD
Fosamprenavir—Nausea—Tamoxifen—pancreatic cancer	0.00109	0.00216	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00109	0.00216	CcSEcCtD
Fosamprenavir—Fatigue—Gemcitabine—pancreatic cancer	0.00109	0.00216	CcSEcCtD
Fosamprenavir—Gastritis—Epirubicin—pancreatic cancer	0.00109	0.00216	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.00108	0.00215	CcSEcCtD
Fosamprenavir—Nausea—Erlotinib—pancreatic cancer	0.00108	0.00214	CcSEcCtD
Fosamprenavir—Decreased appetite—Fluorouracil—pancreatic cancer	0.00108	0.00214	CcSEcCtD
Fosamprenavir—Diarrhoea—Sunitinib—pancreatic cancer	0.00108	0.00213	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.00107	0.00212	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00106	0.0021	CcSEcCtD
Fosamprenavir—Dizziness—Sunitinib—pancreatic cancer	0.00104	0.00206	CcSEcCtD
Fosamprenavir—Abdominal pain—Irinotecan—pancreatic cancer	0.00102	0.00203	CcSEcCtD
Fosamprenavir—Body temperature increased—Irinotecan—pancreatic cancer	0.00102	0.00203	CcSEcCtD
Fosamprenavir—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.00102	0.00203	CcSEcCtD
Fosamprenavir—Gastritis—Doxorubicin—pancreatic cancer	0.00101	0.00199	CcSEcCtD
Fosamprenavir—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.001	0.00199	CcSEcCtD
Fosamprenavir—Vomiting—Sunitinib—pancreatic cancer	0.001	0.00198	CcSEcCtD
Fosamprenavir—Body temperature increased—Gemcitabine—pancreatic cancer	0.000997	0.00198	CcSEcCtD
Fosamprenavir—Neutropenia—Epirubicin—pancreatic cancer	0.000993	0.00197	CcSEcCtD
Fosamprenavir—Rash—Sunitinib—pancreatic cancer	0.000991	0.00197	CcSEcCtD
Fosamprenavir—Dermatitis—Sunitinib—pancreatic cancer	0.00099	0.00196	CcSEcCtD
Fosamprenavir—Headache—Sunitinib—pancreatic cancer	0.000985	0.00195	CcSEcCtD
Fosamprenavir—Body temperature increased—Fluorouracil—pancreatic cancer	0.00098	0.00194	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000958	0.0019	CcSEcCtD
Fosamprenavir—Hypersensitivity—Irinotecan—pancreatic cancer	0.000954	0.00189	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000939	0.00186	CcSEcCtD
Fosamprenavir—Myalgia—Docetaxel—pancreatic cancer	0.000934	0.00185	CcSEcCtD
Fosamprenavir—Nausea—Sunitinib—pancreatic cancer	0.000934	0.00185	CcSEcCtD
Fosamprenavir—Asthenia—Irinotecan—pancreatic cancer	0.000929	0.00184	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000927	0.00184	CcSEcCtD
Fosamprenavir—Neutropenia—Doxorubicin—pancreatic cancer	0.000919	0.00182	CcSEcCtD
Fosamprenavir—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000914	0.00181	CcSEcCtD
Fosamprenavir—Asthenia—Gemcitabine—pancreatic cancer	0.000905	0.00179	CcSEcCtD
Fosamprenavir—Pruritus—Gemcitabine—pancreatic cancer	0.000892	0.00177	CcSEcCtD
Fosamprenavir—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000886	0.00176	CcSEcCtD
Fosamprenavir—Diarrhoea—Irinotecan—pancreatic cancer	0.000886	0.00176	CcSEcCtD
Fosamprenavir—Nervous system disorder—Docetaxel—pancreatic cancer	0.000878	0.00174	CcSEcCtD
Fosamprenavir—Pruritus—Fluorouracil—pancreatic cancer	0.000877	0.00174	CcSEcCtD
Fosamprenavir—Skin disorder—Docetaxel—pancreatic cancer	0.000869	0.00172	CcSEcCtD
Fosamprenavir—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000868	0.00172	CcSEcCtD
Fosamprenavir—Diarrhoea—Gemcitabine—pancreatic cancer	0.000863	0.00171	CcSEcCtD
Fosamprenavir—Dizziness—Irinotecan—pancreatic cancer	0.000856	0.0017	CcSEcCtD
Fosamprenavir—Haemoglobin—Epirubicin—pancreatic cancer	0.000854	0.00169	CcSEcCtD
Fosamprenavir—Anorexia—Docetaxel—pancreatic cancer	0.000853	0.00169	CcSEcCtD
Fosamprenavir—Haemorrhage—Epirubicin—pancreatic cancer	0.00085	0.00168	CcSEcCtD
Fosamprenavir—Diarrhoea—Fluorouracil—pancreatic cancer	0.000849	0.00168	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000839	0.00166	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000835	0.00166	CcSEcCtD
Fosamprenavir—Urethral disorder—Epirubicin—pancreatic cancer	0.000833	0.00165	CcSEcCtD
Fosamprenavir—Vomiting—Irinotecan—pancreatic cancer	0.000823	0.00163	CcSEcCtD
Fosamprenavir—Dizziness—Fluorouracil—pancreatic cancer	0.00082	0.00163	CcSEcCtD
Fosamprenavir—Rash—Irinotecan—pancreatic cancer	0.000816	0.00162	CcSEcCtD
Fosamprenavir—Dermatitis—Irinotecan—pancreatic cancer	0.000816	0.00162	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000816	0.00162	CcSEcCtD
Fosamprenavir—Headache—Irinotecan—pancreatic cancer	0.000811	0.00161	CcSEcCtD
Fosamprenavir—Erythema multiforme—Epirubicin—pancreatic cancer	0.000804	0.00159	CcSEcCtD
Fosamprenavir—Vomiting—Gemcitabine—pancreatic cancer	0.000802	0.00159	CcSEcCtD
Fosamprenavir—Rash—Gemcitabine—pancreatic cancer	0.000795	0.00158	CcSEcCtD
Fosamprenavir—Dermatitis—Gemcitabine—pancreatic cancer	0.000795	0.00158	CcSEcCtD
Fosamprenavir—Haemoglobin—Doxorubicin—pancreatic cancer	0.00079	0.00157	CcSEcCtD
Fosamprenavir—Headache—Gemcitabine—pancreatic cancer	0.00079	0.00157	CcSEcCtD
Fosamprenavir—Cardiac disorder—Epirubicin—pancreatic cancer	0.000789	0.00156	CcSEcCtD
Fosamprenavir—Vomiting—Fluorouracil—pancreatic cancer	0.000789	0.00156	CcSEcCtD
Fosamprenavir—Haemorrhage—Doxorubicin—pancreatic cancer	0.000786	0.00156	CcSEcCtD
Fosamprenavir—Rash—Fluorouracil—pancreatic cancer	0.000782	0.00155	CcSEcCtD
Fosamprenavir—Dermatitis—Fluorouracil—pancreatic cancer	0.000781	0.00155	CcSEcCtD
Fosamprenavir—Decreased appetite—Docetaxel—pancreatic cancer	0.000778	0.00154	CcSEcCtD
Fosamprenavir—Headache—Fluorouracil—pancreatic cancer	0.000777	0.00154	CcSEcCtD
Fosamprenavir—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000777	0.00154	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000773	0.00153	CcSEcCtD
Fosamprenavir—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000773	0.00153	CcSEcCtD
Fosamprenavir—Fatigue—Docetaxel—pancreatic cancer	0.000772	0.00153	CcSEcCtD
Fosamprenavir—Urethral disorder—Doxorubicin—pancreatic cancer	0.000771	0.00153	CcSEcCtD
Fosamprenavir—Nausea—Irinotecan—pancreatic cancer	0.000769	0.00152	CcSEcCtD
Fosamprenavir—Immune system disorder—Epirubicin—pancreatic cancer	0.000768	0.00152	CcSEcCtD
Fosamprenavir—Nausea—Gemcitabine—pancreatic cancer	0.000749	0.00149	CcSEcCtD
Fosamprenavir—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000743	0.00147	CcSEcCtD
Fosamprenavir—Malnutrition—Epirubicin—pancreatic cancer	0.00074	0.00147	CcSEcCtD
Fosamprenavir—Nausea—Fluorouracil—pancreatic cancer	0.000737	0.00146	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000732	0.00145	CcSEcCtD
Fosamprenavir—Cardiac disorder—Doxorubicin—pancreatic cancer	0.00073	0.00145	CcSEcCtD
Fosamprenavir—Flatulence—Epirubicin—pancreatic cancer	0.000729	0.00145	CcSEcCtD
Fosamprenavir—Immune system disorder—Doxorubicin—pancreatic cancer	0.00071	0.00141	CcSEcCtD
Fosamprenavir—Abdominal pain—Docetaxel—pancreatic cancer	0.000708	0.0014	CcSEcCtD
Fosamprenavir—Body temperature increased—Docetaxel—pancreatic cancer	0.000708	0.0014	CcSEcCtD
Fosamprenavir—Malnutrition—Doxorubicin—pancreatic cancer	0.000685	0.00136	CcSEcCtD
Fosamprenavir—Flatulence—Doxorubicin—pancreatic cancer	0.000675	0.00134	CcSEcCtD
Fosamprenavir—Hypersensitivity—Docetaxel—pancreatic cancer	0.00066	0.00131	CcSEcCtD
Fosamprenavir—Asthenia—Docetaxel—pancreatic cancer	0.000642	0.00127	CcSEcCtD
Fosamprenavir—Pruritus—Docetaxel—pancreatic cancer	0.000633	0.00126	CcSEcCtD
Fosamprenavir—Myalgia—Epirubicin—pancreatic cancer	0.00063	0.00125	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000625	0.00124	CcSEcCtD
Fosamprenavir—Diarrhoea—Docetaxel—pancreatic cancer	0.000612	0.00121	CcSEcCtD
Fosamprenavir—Nervous system disorder—Epirubicin—pancreatic cancer	0.000592	0.00117	CcSEcCtD
Fosamprenavir—Dizziness—Docetaxel—pancreatic cancer	0.000592	0.00117	CcSEcCtD
Fosamprenavir—Skin disorder—Epirubicin—pancreatic cancer	0.000586	0.00116	CcSEcCtD
Fosamprenavir—Myalgia—Doxorubicin—pancreatic cancer	0.000583	0.00116	CcSEcCtD
Fosamprenavir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000579	0.00115	CcSEcCtD
Fosamprenavir—Anorexia—Epirubicin—pancreatic cancer	0.000576	0.00114	CcSEcCtD
Fosamprenavir—Vomiting—Docetaxel—pancreatic cancer	0.000569	0.00113	CcSEcCtD
Fosamprenavir—Rash—Docetaxel—pancreatic cancer	0.000564	0.00112	CcSEcCtD
Fosamprenavir—Dermatitis—Docetaxel—pancreatic cancer	0.000564	0.00112	CcSEcCtD
Fosamprenavir—Headache—Docetaxel—pancreatic cancer	0.000561	0.00111	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.00055	0.00109	CcSEcCtD
Fosamprenavir—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000548	0.00109	CcSEcCtD
Fosamprenavir—Skin disorder—Doxorubicin—pancreatic cancer	0.000543	0.00108	CcSEcCtD
Fosamprenavir—Anorexia—Doxorubicin—pancreatic cancer	0.000533	0.00106	CcSEcCtD
Fosamprenavir—Nausea—Docetaxel—pancreatic cancer	0.000532	0.00105	CcSEcCtD
Fosamprenavir—Decreased appetite—Epirubicin—pancreatic cancer	0.000525	0.00104	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000521	0.00103	CcSEcCtD
Fosamprenavir—Fatigue—Epirubicin—pancreatic cancer	0.000521	0.00103	CcSEcCtD
Fosamprenavir—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000509	0.00101	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.000494	0.000979	CcSEcCtD
Fosamprenavir—Decreased appetite—Doxorubicin—pancreatic cancer	0.000486	0.000963	CcSEcCtD
Fosamprenavir—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000482	0.000956	CcSEcCtD
Fosamprenavir—Fatigue—Doxorubicin—pancreatic cancer	0.000482	0.000955	CcSEcCtD
Fosamprenavir—Body temperature increased—Epirubicin—pancreatic cancer	0.000477	0.000946	CcSEcCtD
Fosamprenavir—Abdominal pain—Epirubicin—pancreatic cancer	0.000477	0.000946	CcSEcCtD
Fosamprenavir—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000457	0.000906	CcSEcCtD
Fosamprenavir—Hypersensitivity—Epirubicin—pancreatic cancer	0.000445	0.000882	CcSEcCtD
Fosamprenavir—Body temperature increased—Doxorubicin—pancreatic cancer	0.000442	0.000876	CcSEcCtD
Fosamprenavir—Abdominal pain—Doxorubicin—pancreatic cancer	0.000442	0.000876	CcSEcCtD
Fosamprenavir—Asthenia—Epirubicin—pancreatic cancer	0.000433	0.000859	CcSEcCtD
Fosamprenavir—Pruritus—Epirubicin—pancreatic cancer	0.000427	0.000847	CcSEcCtD
Fosamprenavir—Diarrhoea—Epirubicin—pancreatic cancer	0.000413	0.000819	CcSEcCtD
Fosamprenavir—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000412	0.000816	CcSEcCtD
Fosamprenavir—Asthenia—Doxorubicin—pancreatic cancer	0.000401	0.000795	CcSEcCtD
Fosamprenavir—Dizziness—Epirubicin—pancreatic cancer	0.000399	0.000792	CcSEcCtD
Fosamprenavir—Pruritus—Doxorubicin—pancreatic cancer	0.000395	0.000784	CcSEcCtD
Fosamprenavir—Vomiting—Epirubicin—pancreatic cancer	0.000384	0.000761	CcSEcCtD
Fosamprenavir—Diarrhoea—Doxorubicin—pancreatic cancer	0.000382	0.000758	CcSEcCtD
Fosamprenavir—Rash—Epirubicin—pancreatic cancer	0.000381	0.000755	CcSEcCtD
Fosamprenavir—Dermatitis—Epirubicin—pancreatic cancer	0.00038	0.000754	CcSEcCtD
Fosamprenavir—Headache—Epirubicin—pancreatic cancer	0.000378	0.00075	CcSEcCtD
Fosamprenavir—Dizziness—Doxorubicin—pancreatic cancer	0.000369	0.000732	CcSEcCtD
Fosamprenavir—Nausea—Epirubicin—pancreatic cancer	0.000359	0.000711	CcSEcCtD
Fosamprenavir—Vomiting—Doxorubicin—pancreatic cancer	0.000355	0.000704	CcSEcCtD
Fosamprenavir—Rash—Doxorubicin—pancreatic cancer	0.000352	0.000698	CcSEcCtD
Fosamprenavir—Dermatitis—Doxorubicin—pancreatic cancer	0.000352	0.000698	CcSEcCtD
Fosamprenavir—Headache—Doxorubicin—pancreatic cancer	0.00035	0.000694	CcSEcCtD
Fosamprenavir—Nausea—Doxorubicin—pancreatic cancer	0.000332	0.000658	CcSEcCtD
